… Functional precision cancer medicine … to targeted therapies and limitations of preclinical
models currently used for drug selection have hindered correct validation of precision medicine […

… In conclusion, recent progress in targeted therapy development for AGC has been modest.
The ToGA trial was practice changing for patients with HER-2–overexpressing AGC, for which …

… The discrimination between responders and non-responders before therapy will further
stimulate the development of an individualized therapeutic strategy with a personalized …

… in the development of new medicines and to discuss the … with targeted therapies and
personalized medicine. The rapid development of targeted therapies and personalized medicine is …

… therapies, starting with trastuzumab, directed against HER2 [2]. I think the success with
HER2-targeted therapies … So I think the door of targeted personalized therapies is just starting to …

… Abstract – Personalized medicine is based on: 1) improved … diagnosis of diseases; 2) targeted
therapies of the choice or the … Stratified medicine is a component of personalized medicine …

Hepatocellular carcinoma (HCC) is characterized by a growing number of new cases diagnosed
each year that is nearly equal to the number of deaths from this cancer. In a majority of …

… to targeted therapies. Several different biomarkers have been investigated as predictive
markers of benefit for EGFR-directed therapies, … of EGFR-targeted therapies. Although xenograft …

… field of lung cancer therapy. In this review, we highlight the current targeted therapies in use,
as … In addition, we describe the mechanisms by which these therapies work, as well as why …

… pathogenesis of AML to develop novel targeted therapies. We also discuss the remarkable
… with the prognostic and therapeutic mutations, the novel molecular targeted therapies either …